Cumberland Pharmaceuticals (CPIX) EBT (2010 - 2026)

Cumberland Pharmaceuticals has disclosed EBT across 17 years of filings, most recently posting -$3.1 million for Q1 2026.

• EBT for Q1 2026 came in at -$3.1 million, down 350.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$7.2 million (down 116.84% YoY), and the FY2025 annual result was -$2.8 million, up 56.53% from the prior year.
• EBT came in at -$3.1 million for Q1 2026 at Cumberland Pharmaceuticals, down from -$1.4 million in the prior quarter.
• In the past five years, EBT ranged from a high of $1.3 million in Q1 2025 to a low of -$6.3 million in Q4 2023.
• The 5-year median for EBT is -$1.4 million (2025), against an average of -$1.4 million.
• Across the five-year window, EBT sank 1155.12% in 2024 and surged 166.31% in 2025, its largest moves.
• Cumberland Pharmaceuticals' EBT stood at -$2.4 million in 2022, then sank by 160.29% to -$6.3 million in 2023, then surged by 68.8% to -$2.0 million in 2024, then advanced by 28.92% to -$1.4 million in 2025, then slumped by 125.34% to -$3.1 million in 2026.
• The last three EBT figures came in at -$3.1 million (Q1 2026), -$1.4 million (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.